ihl general, page-243

Great find Hezla! I definitely missed seeing that.

What is apparent to me now is that there is likely delay in gaining clinical literature appraisal for each of the four research areas related to the four novel products.

We got a team of experts on the Med Board now, one for each research/product area. It is likely their responsibility to gather the clinical literature appraisal. Not sure why they are behind on this....

A possible answer is that they are waiting for the best time to do an Investment Roadshow? As honestly, there is no reason why they wouldnt be incentivized to do this, these milestones are what is giving them shares in the company and their only incentive for being on board.

@Glitterati Definitely take this SS Hezla posted into the AGM with you and ask questions if the board hasnt already answered them.
I concur with Hez on this, that there has got to be a reason why they are withholding these updates.... Likely for market-savvy reasons, as they want maximum impact.

Probably will get all this tomorrow morning, see you all then!